CD55 antibody | 67
Mouse anti Human CD55 antibody, clone 67 (MCA1614) used for the identification of CD55 expressing cells in rheumatoid arthritis synovial tissue by immunohistochemistry on cryostat sections.
Image caption:
Representative double staining of rheumatoid arthritis synovial tissue with antibodies against RasGRF1 and cell-specific markers. Synovial tissue sections were stained overnight with antibodies against Ras guanine nucleotide-releasing factor 1(RasGRF1), followed by antibodies against CD3, CD55, and CD68. After biotin tyramide enhancement, staining was developed with amino-ethylcarbazole (red, RasGRF1) and Fast blue (blue, cell-specific markers). Magnification x 100.
From: Abreu JR, de Launay D, Sanders ME, Grabiec AM, van de Sande MG, Tak PP, Reedquist KA.
The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
Arthritis Res Ther. 2009;11(4):R121.
This is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti CD55 antibofdy, clone 67 (MCA1614) used for the demonstration of CD55 and MPGES1 in fibroblasts from sinovial lining by immunofluorescence.
Image caption:
MPGES1 expression in synovial lining fibroblasts before and 16 weeks after initiation of rituximab therapy.
Double immunofluorescence pictures show the presence of MPGES1 (red) expression in CD55 positive fibroblasts (green) in the rheumatoid tissue before rituximab initiation (A) and 16 weeks later (B). Original magnification 500x. Arrows point to double stained cells
From: Gheorghe KR, Thurlings RM, Westman M, Boumans MJ, Malmström V, Trollmo C, et al. (2011)
Prostaglandin E2 Synthesizing Enzymes in Rheumatoid Arthritis B Cells and the Effects of B Cell Depleting Therapy on Enzyme Expression.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human CD55:Alexa Fluor® 488
Mouse anti Human CD55:Alexa Fluor® 647
Mouse anti Human CD55:FITC
Mouse anti Human CD55
Mouse anti Human CD55:RPE
Mouse anti Human CD55:RPE-Alexa Fluor® 647
Mouse anti Human CD55:Alexa Fluor® 700
- Product Type
- Monoclonal Antibody
- Clone
- 67
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA1614A488 | F | 100 Tests/1ml |
|
|
| MCA1614A647 | F | 100 Tests/1ml |
|
|
| MCA1614F | F | 0.1 mg |
|
|
| MCA1614GA | C F WB | 0.1 mg |
|
|
| MCA1614 | C F WB | 0.2 mg |
|
|
| MCA1614PE | F | 100 Tests |
|
|
| MCA1614P647 | F | 100 Tests |
|
|
| MCA1614A700 | F | 100 Tests/1ml |
|
Mouse anti Human CD55 antibody, clone 67 recognizes the human CD55 cell surface antigen, a GPI linked molecule also known as decay accelerating factor (DAF). CD55 is expressed by a wide range of cell types.
CD55 is the complement regulatory protein, decay accelerating factor (DAF) (Lublin and Atkinson 1989). Human CD55 is a ~70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O-glycans, and also on N-glycan. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries theCromer related blood group antigens.
DAF has a wide distribution on cells in non-haematopoietic tissues, particularly epithelium and is found at the fetal-maternal interface in placenta (Holmes et al. 1990 and Yang et al. 2009). Soluble forms of DAF are found, for example, in plasma, saliva and urine (Medof et al. 1987). The antigen on erythrocytes is pronase and chymotrypsin sensitive, but resistant to trypsin.
CD55 is the complement regulatory protein, decay accelerating factor (DAF) (Lublin and Atkinson 1989). Human CD55 is a ~70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O-glycans, and also on N-glycan. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries the
DAF has a wide distribution on cells in non-haematopoietic tissues, particularly epithelium and is found at the fetal-maternal interface in placenta (Holmes et al. 1990 and Yang et al. 2009). Soluble forms of DAF are found, for example, in plasma, saliva and urine (
Product Details
- Target Species
- Human
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 647 - lyophilized
- Product Form
- Purified IgG conjugated to Alexa Fluor® 700 - liquid
- Reconstitution
- Reconstitute with 1 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Carrier Free
- Yes
- Immunogen
- K562 cells
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch
- Guarantee
- 18 months from date of despatch
- Guarantee
- 18 months from date of despatch
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 12 months from date of reconstitution.
- Guarantee
- 12 months from date of reconstitution
- Guarantee
- 18 months from date of despatch
More Information
- UniProt
- P08174 Related reagents
- Entrez Gene
- CD55 Related reagents
- GO Terms
- GO:0005576 extracellular region
- GO:0005887 integral to plasma membrane
- GO:0005625 soluble fraction
- GO:0006958 complement activation, classical pathway
- GO:0007204 elevation of cytosolic calcium ion concentration
- GO:0031225 anchored to membrane
- GO:0045087 innate immune response
- GO:0045121 membrane raft
- GO:0045730 respiratory burst
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Regulatory
- For research purposes only
Applications of CD55 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | |||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/10 | 1/25 | |
| Immunohistology - Frozen | 1/100 | 1/1000 | |
| Western Blotting | |||
| Flow Cytometry | Neat | 1/2 | |
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Histology Positive Control Tissue
- Human Tonsil
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG1 Negative Control:Alexa Fluor® 488 | MCA928A488 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:Alexa Fluor® 647 | MCA928A647 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:FITC | MCA928F | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control | MCA928 | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control:RPE | MCA928PE | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control:RPE-Alexa Fluor® 647 | MCA928P647 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:Alexa Fluor® 700 | MCA928A700 | F | 100 Tests/1ml |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test |
Product Specific References
References for CD55 antibody
-
Hadam, M.R. (1989) In Leucocyte Typing IV: White Cell Differentiation Antigens.
Edited by Knapp, W. et al. Oxford University Press pp 694-697. -
Holmes, C.H. et al. (1990) Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.
J Immunol. 144 (8): 3099-105. -
O'Brien, D.P. et al. (2009) Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor.
J Biol Chem. 283: 23922-30. -
Yang, P. et al. (2009) Expression and modulation of RPE cell membrane complement regulatory proteins.
Invest Ophthalmol Vis Sci. 50: 3473-81. -
van de Sande, M.G. et al. (2011) Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase.
Ann Rheum Dis. 70: 772-7. -
Mo, B. et al. (2006) ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium.
Biol Reprod. 75: 387-94. -
Araten, D.J. et al. (2005) A quantitative measurement of the human somatic mutation rate.
Cancer Res. 65: 8111-7. -
de Launay, D. et al. (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis.
Am J Pathol. 177: 3010-24. -
Gheorghe, K.R. et al. (2011) Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
PLoS One. ;6: e16378. -
Kraan, M.C. et al. (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.
Ann Rheum Dis. 63: 483-8. -
van Holten, J. et al. (2005) A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
Ann Rheum Dis. 64 (1): 64-9. -
Abreu, J.R. et al. (2009) The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
Arthritis Res Ther.11(4):R121. -
Thurlings, R.M. et al. (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
Ann Rheum Dis. 67 (7): 917-25. -
Vos, K. et al. (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Arthritis Rheum. 56 (3): 772-8. -
Edginton S et al. (2016) Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium.
J Rheumatol. 43 (5): 846-54.
Further Reading
-
Lublin, D.M. & Atkinson, J.P. (1989) Decay-accelerating factor: biochemistry, molecular biology, and function.
Annu Rev Immunol. 7: 35-58. -
Daniels, G. (1989) Cromer-related antigens--blood group determinants on decay-accelerating factor.
Vox Sang. 56 (4): 205-11.
